Fast-Acting Insulin Aspart and Insulin Pump Settings
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
To clarify the role of fast-acting insulin aspart (Fiasp) in insulin pump-treated type 1
diabetes more research is needed.
The aim of this study is twofold:
1. to compare the effects of Fiasp and Iasp in adults with type 1 diabetes who are using
insulin pump and CGM and who are attending a diabetes out-patient clinic with extensive
expertise in insulin pump and CGM therapy.
2. to determine differences in insulin pump settings when insulin pumps are optimally
adjusted to each of the two insulin types.